MK-1697

MK-1697 · Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-1697, covering 2021-02-12 to 2021-02-12. Get the full timeline:

Most recent: Clinical Trial Update: Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001) [Phase 1]